Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Jun 13, 2023 1:57pm
242 Views
Post# 35494201

RE:RE:FDA Breakthrough application is still alive

RE:RE:FDA Breakthrough application is still alive
ScienceFirst wrote: Unless FDA decided otherwise.

But clearly, it wouldn't be the decision of TLT not to apply for, for all the many benefits such designation would bring.

But lets assume the worse case scenario, where they would suddenly not apply for Breakthrough designation for whatever reason.  We know that data could entice a big pharma to sign a jv much before 2025/2026 in order to make sure it has clinched a deal

But then again, TLT would not have bothered Dr. Kulkarni/Dr.Kamat to shot an interview at the last AUA, if the focus was to take the long road.

Good point ScienceFirst,  the AUA was a hit out of the ball park followed by the announcement of the hiring of  both a biostatistics  & regulatory organization to present a clearer picture of data on patients also out of the ball park. And the grand slam of all is the hiring of Dr. Kaouthar  Lbiati.  
Well as a kid I played the game Clue and was pretty good at it, as a Clue Master all these recent moves by Theralase says we are a winner. 
<< Previous
Bullboard Posts
Next >>